Evidence map›Paper›PMID 20690197›Full record

ArticleCancer2010

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.

Matthew R Cooperberg, Andrew J Vickers, Jeanette M Broering, Peter R Carroll

Erratum issued 2 registry-linked trialsOpen access · bronzeAbstract readComparative StudyEvaluation Study
In one paragraph

Article in Cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 115 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 6 pooled it
22.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02454543 naactive not recruitingnot on this mapstarted 2015, after this paper: background citation

Multicentric, Prospective, Randomized Controlled Trial Comparing Best Systemic Therapy (BST) With Radical Prostatectomy or BST Alone in the Management of Men With Pauci-metastatic Prostate Cancer

TypeinterventionalSponsorMartini-Klinik am UKE GmbHRan2015 to 2026Enrolled452ConditionsProstate CancerArmsRadical prostatectomy, Best systemic therapy
NCT04854369 no longer availablenot on this map

68Ga-PSMA-11 Patients With Newly Diagnosed and Recurrent Prostate Cancer

Typeexpanded_accessSponsorTulane UniversityConditionsProstatic Neoplasms, Prostatic Neoplasms, Castration-ResistantArms68 Ga-PSMA-11 prepared using a PSMA-11 Sterile Cold Kit
3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 6 syntheses or guidelines pooled it, 311 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. The direct prognosis comparison ofEuropean journal of medical research · 2023
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Matthew R CooperbergDepartment of Urology, University of California, San Francisco, CA, USA. mcooperberg@urology.ucsf.edu
Andrew J Vickers
Jeanette M Broering
Peter R Carroll
UCSF Helen Diller Family Comprehensive Cancer Center · USMemorial Sloan Kettering Cancer Center · US

Funding

UCSF PROSTATE CANCER SPOREP50CA089520 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CARROLL, PETER R · 2000 to 2008
$13.9M
NCI NIH HHS P50 CA089520NCI NIH HHS P50CA89520
6 · The paper itself

Abstract

backgroundBecause no adequate randomized trials have compared active treatment modalities for localized prostate cancer, the authors analyzed risk-adjusted, cancer-specific mortality outcomes among men who underwent radical prostatectomy, men who received external-beam radiation therapy, and men who received primary androgen-deprivation therapy.

methodsThe Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) registry comprises men from 40 urologic practice sites who are followed prospectively under uniform protocols, regardless of treatment. In the current study, 7538 men with localized disease were analyzed. Prostate cancer risk was assessed using the Kattan preoperative nomogram and the Cancer of the Prostate Risk Assessment (CAPRA) score, both well validated instruments that are calculated from clinical data at the time of diagnosis. A parametric survival model was constructed to compare outcomes across treatments adjusting for risk and age.

resultsIn total, 266 men died of prostate cancer during follow-up. Adjusting for age and risk, the hazard ratio for cancer-specific mortality relative to prostatectomy was 2.21 (95% confidence interval [CI], 1.50-3.24) for radiation therapy and 3.22 (95% CI, 2.16-4.81) for androgen deprivation. Absolute differences between prostatectomy and radiation therapy were small for men at low risk but increased substantially for men at intermediate and high risk. These results were robust to a variety of different analytic techniques, including competing risks regression analysis, adjustment by CAPRA score rather than Kattan score, and examination of overall survival as the endpoint.

conclusionsProstatectomy for localized prostate cancer was associated with a significant and substantial reduction in mortality relative to radiation therapy and androgen-deprivation monotherapy. Although this was not a randomized study, given the multiple adjustments and sensitivity analyses, it is unlikely that unmeasured confounding would account for the large observed differences in survival.

Indexed as

ProstatectomyAgedAndrogen AntagonistsHumansMaleMiddle AgedProstatic NeoplasmsRiskTreatment OutcomeAndrogen Antagonists

Identifiers

PMID20690197
PMCPMC2975879
OpenAlexW2081994609

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.